Centinel focuses exclusively on treating cervical and lumbar spinal disease with its total disc replacement technology platform.
Prodisc cervical revenue reached $43 million, up 69% year over year. Prodisc lumbar revenue was also up 36% year over year.
Nearly 800 surgeons used Prodisc portfolio products in 2023, representing a 44% growth. 2023 also saw 250 new Prodisc users. Sales in ASCs also grew 56% year-over-year.
In 2023, Centinel launched the Prodisc C Vivo system and the Prodisc C SK, which saw nearly 3,700 procedures through the end of the year. The new systems drove a nearly 90% increase in full-year U.S. Prodisc cervical revenue and added an average of nearly 100 new surgeons per quarter.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
